ReviewBiomedicines2026
Heart Rate Variability in Cardiometabolic Disease: From Molecular Mechanisms to Personalized Exercise Prescription.
Review in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiometabolic diseases are characterized by interconnected disturbances in metabolic, inflammatory, mitochondrial, vascular, endocrine, and autonomic regulation, highlighting the need for integrative biomarkers capable of capturing systemic physiological dysfunction. Heart rate variability (HRV) provides a non-invasive and dynamic measure of cardiovascular autonomic regulation and may reflect the cumulative physiological consequences of these interacting alterations. This narrative review synthesizes current evidence on the role of HRV in cardiometabolic disease, with particular emphasis on the molecular and physiological mechanisms linking autonomic dysfunction with metabolic, inflammatory, mitochondrial, and vascular disturbances, as well as its potential application in individualized exercise prescription. Across obesity, metabolic syndrome, insulin resistance, type 2 diabetes, hypertension, and cardiovascular disease, reduced HRV is consistently associated with impaired autonomic adaptability and increased cardiometabolic risk. However, HRV should not be interpreted as a direct measure of sympathovagal balance or as a molecular biomarker; rather, it represents an integrative physiological signal influenced by multiple biological, behavioral, and environmental factors. Exercise may modulate autonomic regulation while simultaneously influencing metabolic signaling, inflammation, mitochondrial function, vascular health, and recovery, and accumulating evidence indicates that improvements in HRV may accompany favorable adaptations across diverse cardiometabolic populations. Accordingly, repeated HRV assessment may complement clinical, metabolic, functional, and body-composition measures to characterize physiological adaptation and support individualized adjustments in exercise prescription. Overall, HRV represents a promising integrative marker of cardiometabolic health and physiological resilience. Nevertheless, methodological heterogeneity, physiological confounding, and limited causal evidence currently constrain its clinical implementation. Standardized longitudinal and mechanistic studies are warranted to establish clinically meaningful HRV phenotypes, determine their capacity to predict individual exercise responsiveness, and clarify whether HRV-guided interventions can ultimately improve cardiometabolic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.